Anti-infective vaccination in the 21st century-new horizons for personal and public health (Q26783530)

1

0 references

Kena Swanson

2

0 references

Luke Green

3

0 references

Annaliesa S Anderson

Current Opinion in Microbiology

5

0 references

language of work or name

English

0 references

publication date

October 2015

0 references

published in

0 references

volume

27

0 references

page(s)

96-102

0 references

cites work

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Rotavirus vaccines: a story of success

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Rotavirus vaccines: successes and challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Rotavirus vaccines WHO position paper: January 2013 - Recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Development status and future prospects for a vaccine against Chlamydia trachomatis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Towards a safe and effective chlamydial vaccine: lessons from the eye

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

A new method of non-cross-linking conjugation of polysaccharides to proteins via thioether bonds for the preparation of saccharide-protein conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

FDA approves new upgraded Gardasil 9.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

The global distribution and burden of dengue

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

1 reference

7 January 2021

Dengue: a continuing global threat

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Microbiota and pelvic inflammatory disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Effectiveness of maternal influenza immunization in mothers and infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Treatment with monoclonal antibodies against Clostridium difficile toxins

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Influenza vaccination of pregnant women and protection of their infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Efficacy of a tetravalent dengue vaccine in children in Latin America.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Detecting species-site dependencies in large multiple sequence alignments

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Vaccinations for pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

NadA diversity and carriage in Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Prophylactic human papillomavirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

HIV-1 vaccine immunogen design strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

New conjugate vaccines for the prevention of pneumococcal disease in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Global prevailing and emerging pediatric pneumococcal serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

Challenges in the design of a T cell vaccine in the context of HIV-1 diversity

1 reference

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.MIB.2015.07.006

1 reference

7 January 2021